文献速递食管胃疾病与幽门螺杆菌消化道肿瘤与早癌

表皮生长因子受体抑制下调幽门螺杆菌诱导的上皮炎症反应、DNA损伤及胃癌发生

Epidermal growth factor receptor inhibition downregulates Helicobacter pylori-induced epithelial inflammatory responses, DNA damage and gastric carcinogenesis.
PubMed 文献 · Gut · 2017-05-04

该研究在多种小鼠及沙鼠模型中评估表皮生长因子受体(EGFR)抑制剂吉非替尼及上皮细胞特异性Egfr敲除对幽门螺杆菌诱导的胃炎和胃癌的作用。结果显示吉非替尼减少趋化因子表达、炎症细胞浸润和DNA损伤,并减少异型增生和癌变,且可阻断MAPK1/3和AP-1活化。作者认为上皮EGFR抑制可能成为预防幽门螺杆菌感染者胃癌的策略。

要点

  • 吉非替尼减少幽门螺杆菌感染C57BL/6小鼠胃上皮细胞Cxcl1和Cxcl2表达及黏膜炎症细胞和DNA损伤。
  • 上皮细胞特异性Egfr敲除小鼠同样出现趋化因子、炎症细胞和DNA损伤的类似减少。
  • 在INS-GAS小鼠和沙鼠中,吉非替尼显著减少异型增生和癌变,并阻断MAPK1/3和AP-1活化。

核心结论

  • 上皮EGFR抑制可能是预防幽门螺杆菌感染者发生胃癌的潜在策略。

研究设计与样本

  • 研究使用C57BL/6小鼠、上皮细胞特异性Egfr敲除(EfgrΔepi)小鼠及其对照(Egfrfl/fl)、幽门螺杆菌感染的胰岛素-胃泌素(INS-GAS)转基因小鼠和沙鼠,评估吉非替尼的化学预防作用。

主要发现

  • 在C57BL/6小鼠中,吉非替尼减少胃上皮细胞Cxcl1和Cxcl2表达、黏膜髓过氧化物酶阳性炎症细胞及幽门螺杆菌诱导的上皮DNA损伤。
  • 在感染的EfgrΔepi小鼠与Egfrfl/fl对照小鼠中,趋化因子、炎症细胞和DNA损伤出现类似减少。
  • 在幽门螺杆菌感染的INS-GAS小鼠和沙鼠中,吉非替尼治疗显著减少异型增生和癌变。
  • 吉非替尼阻断胃上皮细胞中幽门螺杆菌诱导的MAPK1/3和激活蛋白1活化,从而抑制趋化因子合成。
  • 在吉非替尼治疗的感染野生型和INS-GAS小鼠胃组织及EfgrΔepi小鼠原代上皮细胞中,MAPK1/3磷酸化和JUN活化降低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Gastric cancer is the third leading cause of cancer death worldwide and infection by Helicobacter pylori is the strongest risk factor. We have reported increased epidermal growth factor receptor (EGFR) phosphorylation in the H. pylori-induced human carcinogenesis cascade, and association with DNA damage. Our goal was to determine the role of EGFR activation in gastric carcinogenesis. DESIGN: We evaluated gefitinib, a specific EGFR inhibitor, in chemoprevention of H. pylori-induced gastric inflammation and cancer development. Mice with genetically targeted epithelial cell-specific deletion of Egfr (EfgrΔepi mice) were also used. RESULTS: In C57BL/6 mice, gefitinib decreased Cxcl1 and Cxcl2 expression by gastric epithelial cells, myeloperoxidase-positive inflammatory cells in the mucosa and epithelial DNA damage induced by H. pylori infection. Similar reductions in chemokines, inflammatory cells and DNA damage occurred in infected EgfrΔepi versus Egfrfl/fl control mice. In H. pylori-infected transgenic insulin-gastrin (INS-GAS) mice and gerbils, gefitinib treatment markedly reduced dysplasia and carcinoma. Gefitinib blocked H. pylori-induced activation of mitogen-activated protein kinase 1/3 (MAPK1/3) and activator protein 1 in gastric epithelial cells, resulting in inhibition of chemokine synthesis. MAPK1/3 phosphorylation and JUN activation was reduced in gastric tissues from infected wild-type and INS-GAS mice treated with gefitinib and in primary epithelial cells from EfgrΔepi versus Egfrfl/fl mice. Epithelial EGFR activation persisted in humans and mice after H. pylori eradication, and gefitinib reduced gastric carcinoma in INS-GAS mice treated with antibiotics. CONCLUSIONS: These findings suggest that epithelial EGFR inhibition represents a potential strategy to prevent development of gastric carcinoma in H. pylori-infected individuals.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Sierra JC, Asim M, Verriere TG, et al. Epidermal growth factor receptor inhibition downregulates Helicobacter pylori-induced epithelial inflammatory responses, DNA damage and gastric carcinogenesis. Gut. 2017. PMID: 28473630. doi:10.1136/gutjnl-2016-312888

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。